Source : Diagnostica Stago, Inc.
April 1, 2010, Parsippany, NJ, USA – Diagnostica Stago, Inc. (DSI), recently finalized the acquisition of
Thrombinoscope BV, based in Maastricht, The Netherlands. This company, originally developed at
Maastricht University, researches, develops and markets thrombin generation (TG) systems through the
use of the Calibrated Automated Thrombogram
(CAT) system. This system is available for research-only
use – and should not be used for diagnostic purposes.
“The development potential of this new TG approach in hemostasis using the CAT system is very
promising,” noted Stephane Zamia, PhD and CEO of DSI. “The addition of this approach to Stago’s portfolio
will allow our customers to measure TG in real-time and in larger, scalable studies.”
What is Thrombin generation (TG)?
TG is a universal test capable of assessing a patient’s global hemostatic balance in the case of hemorrhage
or thrombosis. Few methods previously existed that allowed for TG standardization and calibration.
Thrombinoscope introduced a patented, sample-specific calibrator that allows for error correction due to
inter-subject plasma composition and color variations, as well as substrate consumption. This method is
both specific and sensitive, thus giving increased relevance to this hemostatic test in academic research
centers, pharmaceutical companies and contract research organizations.
About Diagnostica Stago, Inc.
Diagnostica Stago, Inc. is the exclusive provider of the Diagnostica Stago Hemostasis product lines in the
United States and offers a complete system of coagulation instruments and optimized reagent kits for
research as well as for routine analysis. Diagnostica Stago, Inc. is the U.S. subsidiary of Diagnostica Stago,
S.A.S. France, a leader in the development and manufacture of Hemostasis products. For more information
about any Stago product or service, please call 800-222-COAG or visit our website at www.stago-us.com.